natur
abund
sourc
novel
drug
discoveri
lycorin
natur
alkaloid
immens
therapeut
potenti
lycorin
activ
low
concentr
high
specif
number
cancer
vivo
vitro
variou
drugresist
cancer
cell
review
summar
therapeut
effect
anticanc
mechan
lycorin
time
discuss
pharmacolog
compar
structureact
relationship
anticanc
activ
compound
research
outlin
paper
serv
foundat
explain
lycorin
import
lead
compound
new
gener
anticanc
drug
design
provid
principl
develop
biolog
strategi
util
lycorin
treatment
cancer
throughout
age
organ
compound
terrestri
marin
organ
appli
treatment
wide
spectrum
diseas
particularli
plant
richest
sourc
basi
tradit
medicin
histori
use
plant
plantderiv
substanc
date
back
bce
past
fifti
year
develop
combinatori
chemistri
highthroughput
screen
method
made
natur
product
relat
structur
extrem
import
element
pharmacopeia
studi
chin
et
al
new
drug
launch
origin
natur
sourc
search
anticanc
agent
natur
sourc
date
back
discoveri
develop
vinca
alkaloid
vinblastin
vincristin
isol
cytotox
podophyllotoxin
took
almost
year
drug
came
clinic
usag
among
drug
prescrib
current
cancer
treatment
deriv
plant
includ
vinca
alkaloid
vinblastin
vincristin
vindesin
vinorelbin
taxan
paclitaxel
docetaxel
podophyllotoxin
deriv
topotecan
irinotecan
anthracyclin
doxorubicin
daunorubicin
epirubicin
idarubicin
plant
tradit
chines
medicin
rich
host
novel
drug
discoveri
tradit
medicin
use
treatment
ailment
rang
cough
cold
parasit
infect
inflamm
amaryllidacea
famili
plant
lycori
radiat
ornament
chines
medicin
plant
amaryllidacea
famili
plant
well
known
extens
sourc
pharmacolog
activ
alkaloid
lycorin
first
among
alkaloid
isol
plant
narcissu
pseudonarcissu
onward
lycorin
deriv
draw
interest
medicin
field
due
diverg
chemic
structur
strong
biolog
effect
fig
review
focu
divers
pharmacolog
function
anticanc
mechan
lycorin
associ
pharmacochem
characterist
pyrrolophenanthridin
alkaloid
lycorin
found
variou
amaryllidacea
speci
amaryllidacea
famili
herbac
perenni
bulbou
flower
plant
compound
isol
amaryllidacea
plant
known
medicin
properti
millenari
frequent
report
amaryllidacea
speci
contain
lycorin
includ
lycori
radiat
leucojum
aestivum
hymenoc
littorali
hippeastrum
equestr
flower
clivia
nobili
ammochari
coranica
brunsvigia
radulosa
crinum
macowanii
leucojum
aestivum
lycorin
obtain
asymmetr
chemic
synthesi
total
synthesi
strategi
also
applic
gener
deriv
lycorin
amaryllidacea
provid
great
divers
biolog
potenti
alkaloid
shown
aris
biosynthet
common
intermedi
norbelladin
norbelladin
undergo
differ
cycliz
rearrang
elimin
andor
recycl
provid
varieti
skeleton
lycorin
compris
analog
possess
orthopara
coupl
doubl
bond
cring
fig
full
chemic
name
lycorin
dioxol
pyrrol
molecular
formula
c
h
rel
molecular
mass
lycorin
colorless
crystal
melt
point
immisc
wastewat
insolubl
ether
alcohol
biolog
activ
lycorin
firmli
associ
structur
exampl
antitumorigen
effect
lycorin
extens
attribut
structur
discuss
later
articl
slight
modif
certain
group
render
compound
either
less
activ
inact
fig
structur
paramet
provid
signific
contribut
activ
includ
presenc
planar
molecul
olefin
dioxol
ring
function
hydroxyl
group
presenc
posit
charg
nitrogen
amin
group
first
report
activ
lycorin
inhibitor
termin
protein
synthesi
found
poliovirusinfect
hela
cell
subsequ
studi
lycorin
show
moder
potent
antivir
activ
reduc
viral
titer
herp
simplex
viru
retroviru
sever
acut
respiratori
syndrom
associ
coronaviru
polioviru
west
nile
viru
wnv
dengu
yellow
fever
virus
enteroviru
influenza
viru
hepat
c
viru
adult
zika
viru
vector
aed
aegypti
lycorin
could
exert
antivir
activ
alphaviru
western
equin
enceph
viru
rhabdoviru
vesicular
stomat
viru
suggest
select
antivir
spectrum
compound
antivir
effect
lycorin
due
multipl
inhibit
block
viral
polymeras
activ
elong
viral
polyprotein
protein
synthesi
structureact
analysi
reveal
free
hydroxyl
group
intact
benzodioxol
group
are
basic
nitrogen
doubl
bond
crucial
antiviru
activ
lycorin
main
metabolit
lycorin
degrad
ungeremin
carbam
substitut
lycorin
stronger
antibacteri
activ
toward
fish
bacteri
pathogen
flavobacterium
columnar
isol
lycorin
lycorin
though
show
almost
inhibitori
activ
gramneg
escherichia
coli
gramposit
staphylococcu
aureu
recent
studi
bendaif
colleagu
demonstr
antibactericid
effect
lycorin
sever
bacteri
strain
suggest
preferenti
antibiot
properti
lycorin
lycorin
found
potent
alkaloid
plasmodium
falciparum
tribolium
castaneumand
aphi
gossypii
compound
abolish
nucleosid
triphosph
diphosphohydrolas
ntpdase
activ
trichomona
vaginalisin
also
caus
cell
cycl
arrest
parasit
lycorin
show
signific
inhibit
dna
topoisomerasei
activ
requir
cell
growth
parasit
timelin
histori
lycorin
first
isol
narcissia
narcissu
pseudonarcissu
l
alkaloid
later
name
lycorin
research
perform
establish
molecular
formula
gener
properti
compound
confirm
chemic
properti
sever
studi
lycorin
investig
vitro
properti
form
foundat
current
knowledg
pharmacolog
potent
alkaloid
lycorin
lycorin
like
amaryllidacea
alkaloid
gener
common
precursor
norbelladin
norbelladin
undergo
analog
possess
group
are
orthopara
coupl
cring
produc
lycorin
b
structureact
relationship
lycorin
anticanc
properti
lycorin
larg
depend
structur
red
shade
indic
part
lycorin
requir
absolut
exert
activ
green
shade
mean
part
chang
chemic
modif
yellow
shade
repres
part
replac
suitabl
group
lycorinetyp
alkaloid
acetylcaranin
dehydrolycorin
potent
inhibitori
activ
malaria
parasit
howev
anoth
lycoranecompound
hippadin
slight
structur
differ
conjug
substitut
tetrahydro
phenanthridin
moieti
inact
therefor
structur
charact
compound
seem
affect
plasmodium
inhibitori
activ
greatli
promis
vari
degre
antiyeast
properti
lycorin
detect
sever
strain
saccharomyc
cerevisia
cryptococcu
laurentii
candida
albican
antiparasit
effect
lycorin
depend
mitochondri
gene
strain
lack
mitochondri
genom
found
resist
high
concentr
compound
lycorin
precursor
norbelladin
act
antiinflammatori
compound
inhibit
activ
express
inflammationrel
cyclooxygenas
rel
lower
concentr
inhibit
signal
lycorin
suppress
endplatechondrocyt
degener
prevent
intervertebr
disc
degener
pathway
lycorin
block
sever
proinflammatori
molecul
exampl
diminish
calprotectininfluenc
inflamm
target
calprotectin
block
lipopolysaccharid
lp
induc
product
proinflammatori
mediat
nitric
oxid
prostaglandin
suppress
stat
activ
lycorin
possess
signific
antiinflammatori
hepatoprotect
effect
mice
dose
rang
mgkg
lycorineinduc
inhibit
hematolog
malign
may
also
contribut
antiinflammatori
activ
degrad
acetylcholin
ach
acetylcholinesteras
ach
lead
brain
cholinerg
dysfunct
alzheim
diseas
ad
patient
therefor
ach
provid
novel
therapeut
target
ad
assoanin
lycorin
type
alkaloid
demonstr
ach
inhibitor
much
lower
ic
antiad
drug
galanthamin
lycorin
also
analges
choleret
bodytemperatur
lower
activ
jimenez
colleagu
first
found
antitumor
activ
lycorin
sinc
numer
research
conduct
discov
antineoplast
activ
lycorin
found
potent
antitumor
compound
variou
kind
cancer
cell
lycorin
also
effect
tumor
xenograft
effect
inhibit
tumor
growth
melanomabear
mice
xenograft
scid
mice
ovarian
cancer
bear
nude
mice
multipl
myeloma
mm
cell
xenograft
nodscid
mice
sever
criteria
lycorineinduc
antitumor
activ
make
compound
interest
research
tool
anticanc
drug
design
specif
select
lycorin
toward
cancer
cell
import
criterion
among
concentr
significantli
reduc
viabil
cancer
cell
trivial
toxic
blymphocyt
normal
peripher
mononuclear
cell
fibroblast
cell
normal
breast
prostat
urotheli
cell
mammari
epitheli
cell
even
plasma
cell
healthi
donor
low
concentr
lycorin
effect
low
singledigit
micromolar
concentr
report
studi
suggest
ic
valu
usual
exceed
tabl
less
toxic
lycorin
well
toler
minim
toxic
well
studi
tumor
xenograft
mous
model
reveal
mg
kgday
lycorin
tumorbear
mice
induc
signific
chang
bodi
weight
indic
exhibit
evid
sign
toxic
high
potenc
lycorin
enhanc
effect
system
use
anticanc
drug
instanc
lesser
toxic
firstlin
chemotherapeut
drug
recent
ying
colleagu
show
mous
breasttumor
cell
line
orthotop
xenograft
model
lycorin
potent
toxoid
paclitaxel
treatment
paclitaxel
led
signific
loss
bodi
weight
lycorin
display
neglig
chang
indic
occurr
less
toxic
compound
chronic
lymphocyt
leukemia
cll
cell
lymph
node
engag
ligand
l
express
tcell
stimul
prolifer
protect
apoptot
signal
studi
show
continu
presenc
l
either
dasatinib
combin
dasatinib
fludarabin
bezafibr
medroxyprogesteron
acet
mpa
fail
induc
apoptosi
cll
addit
lycorin
third
agent
abl
overcom
l
protect
effect
bezafibr
plu
mpa
desir
induct
apoptosi
compound
synerg
effect
antibodi
target
cytotox
tlymphocyt
associ
protein
renal
cell
carcinoma
sensit
resist
lycorin
synthet
intermedi
sensit
adriamycin
doxorubicin
resist
cell
furthermor
recent
studi
found
lycorin
activ
dexamethason
sensit
resist
myeloma
cell
compound
enhanc
bortezomib
activ
resensit
resist
mm
cell
bortezomib
well
inhibit
bortezomib
induc
autophagi
cellular
process
provok
acquir
resist
proteasom
inhibitor
lycorin
also
exhibit
signific
antitumor
activ
apoptosisresist
cancer
cell
find
taken
togeth
provid
intens
potenti
lycorin
singl
agent
combin
agent
counteract
cancer
mechan
antitumor
activ
lycorin
apoptosi
common
antitumor
mechan
natur
compound
oper
mitochondriadepend
intrins
death
receptordepend
extrins
pathway
mitochondri
apoptosi
pathway
associ
famili
member
prosurviv
bclxl
proapoptot
bax
bak
bid
protein
regul
disrupt
mitochondri
outer
membran
cytochrom
c
releas
cytochrom
c
releas
disrupt
mitochondria
initi
activ
scaffold
protein
apoptot
proteaseactiv
factor
wherea
releas
protein
smac
second
mitochondriaderiv
activ
caspas
block
caspas
inhibitor
xiap
xlink
inhibitor
apoptosi
protein
therebi
promot
apoptosi
death
receptormedi
extrins
pathway
apoptosi
activ
certain
death
receptor
ligand
tumor
necrosi
factor
tnf
famili
fa
ligand
tnf
engag
cognat
death
receptor
fa
respect
plasma
membran
lead
activ
lycorin
strong
apoptosi
induc
induc
mitochondri
death
receptormedi
apoptosi
cancer
cell
effect
lycorin
cell
apoptosi
analyz
breast
cancer
bladder
cancer
hematolog
malign
includ
leukemia
myeloma
found
induc
mitochondri
intrins
apoptot
pathway
lycorin
downregul
express
antiapoptot
famili
protein
increas
express
proapoptot
bax
famili
protein
also
suggest
potenti
molecular
target
lycorineinduc
apoptosi
fig
downregul
lycorin
translat
level
induc
apoptosi
cytochrom
c
releas
caspas
activ
leukemia
cell
lack
without
discern
chang
level
bax
bak
bik
bid
xiap
breast
cancer
bladder
cancer
cell
lycorin
suppress
pathway
correspond
increas
express
neg
regul
pakt
pten
protein
level
activ
intrins
apoptosi
cascad
expression
chang
pathway
associ
urinari
bladder
cancer
promis
therapeut
potenti
lycorin
diseas
lycorin
also
induc
apoptosi
lung
cancer
cell
mtor
pathway
induct
extrins
death
receptor
pathway
apoptosi
lycorin
report
activ
death
receptor
ligand
tumor
necrosi
factor
tnf
famili
lead
caspas
activ
also
found
lycorin
decreas
substrat
bid
significantli
increas
express
level
truncat
form
bid
protein
tbid
concomit
releas
cytochrom
c
activ
indic
bid
mediat
crosstalk
mitochondria
death
receptor
apoptot
pathway
upon
lycorin
treatment
lycorin
also
increas
portion
apoptot
cell
vivo
xenograft
tumor
model
lycorin
suggest
effect
compound
induc
apoptosi
number
cancer
induct
apoptosi
probabl
princip
mechan
action
lycorin
exert
antitumor
effect
solid
tumor
lycorin
inhibit
prolifer
migrat
panel
glioma
melanoma
cell
line
resist
apoptosi
addit
lycorin
induc
apoptosi
glioma
nonsmal
cell
lung
cancer
cell
display
resist
variou
proapoptot
stimuli
rather
exhibit
cytostat
effect
impair
actin
cytoskeleton
organ
lead
inhibit
cell
migrat
prolifer
mode
action
lycorin
account
inhibit
prolifer
migrat
cell
display
resist
apoptosi
suggest
compound
excel
lead
combat
cancer
natur
resist
proapoptot
stimuli
lycorin
induc
cell
cycl
arrest
phase
depend
cancer
type
fig
cell
cycl
phasespecif
cyclin
cyclindepend
kinas
cdk
cipkip
ink
famili
cdk
inhibitor
cki
orchestr
progress
cell
phase
lycorin
induc
phase
cell
cycl
arrest
multipl
myeloma
chronic
myelocyt
leukemia
cell
line
downregul
cyclin
wherea
ovarian
cancer
cell
line
acut
promyelocyt
leukemia
cell
line
compound
induc
cell
cycl
arrest
phase
respons
growth
factor
combin
one
sever
dtype
cyclin
earli
phase
later
phase
cyclin
e
cyclin
synthes
form
conjug
phosphoryl
retinoblastoma
rb
protein
allow
dissoci
rb
transcript
factor
target
gene
express
mitogen
signal
promot
cell
cycl
progress
phase
phase
mediat
activ
cyclin
bassoci
key
member
cipkip
cyclindepend
kinas
inhibitor
famili
bind
directli
inhibit
activ
cyclin
cyclin
regardless
cancer
cell
type
lycorin
increas
express
henc
suggest
mediat
lycorineinduc
cell
cycl
arrest
either
phase
tumor
suppressor
regul
express
activ
although
lycorin
induc
express
inhibit
cell
cycl
progress
upstream
effector
upregul
lycorin
clear
yet
lycorin
found
upregul
express
upstream
induc
howev
also
upregul
leukemia
cell
line
therefor
impli
upregul
mediat
pathway
possibl
direct
target
lycorin
exert
cell
cycl
inhibitori
activ
compound
necrosi
formal
regard
accident
cell
death
howev
upon
dna
damag
cell
undergo
necrosi
program
regul
way
consequ
normal
physiolog
process
although
control
manner
similar
apoptosi
necrosi
caspas
expend
process
involv
signal
pathway
distinct
apoptot
cell
death
receptorinteract
protein
receptorinteract
act
initi
effector
act
inhibitor
necrosi
studi
found
lycorin
lead
program
necrosi
upregul
express
necrosisinduc
effect
lycorin
also
associ
mitochondri
dysfunct
reactiv
oxygen
speci
ro
gener
atp
deplet
dna
damag
fig
autophagi
compon
stress
manag
system
cell
util
cell
remov
defect
organel
autophagi
act
surviv
strategi
establish
advanc
tumor
maintain
cellular
energi
level
enhanc
chemosensit
number
anticanc
agent
induc
cell
death
clear
yet
autophagi
mediat
prosurviv
effect
cancer
cell
mechan
may
involv
limit
dnadamag
responsemedi
apoptosi
activ
highmobl
group
box
receptor
advanc
glycat
end
product
rage
signal
axi
human
highmobl
group
box
protein
amino
acid
residu
molecul
name
electrophoret
mobil
polyacrylamid
gel
implic
sever
human
diseas
includ
signific
involv
oncogenesi
action
depend
subcellular
local
molecul
import
stress
signal
well
autophagi
activ
play
extracellular
cytoplasm
nuclear
function
lycorin
inhibit
autophagi
downregul
express
fig
lycorineinduc
proteasom
degrad
inhibit
activ
mekerk
signal
pathway
therebi
decreas
phosphoryl
lead
constitut
associ
eventu
result
autophagi
inhibit
combin
studi
possibl
link
anticanc
effect
lycorin
postul
fig
autophagi
key
cellular
process
turnov
damag
mitochondria
cell
mitochondria
main
sourc
cellular
ro
inhibit
autophagi
lycorin
increas
accumul
damag
mitochondria
cell
although
confirm
probabl
damag
mitochondria
sourc
increas
ro
lycorin
treatment
lead
atp
deplet
dna
damag
result
necrot
cell
death
hand
cell
cycl
arrest
follow
dna
damag
critic
characterist
prohibit
cell
go
mitosi
henc
possibl
cell
cycl
arrest
observ
lycorin
treatment
result
dna
damag
caus
compound
therefor
lycorineinduc
dna
damag
may
caus
activ
inhibit
cell
cycl
ultim
lead
apoptot
death
cell
howev
link
cellular
effect
induc
lycorin
experiment
prove
research
demand
clarifi
mechan
addit
effect
lycorin
cell
death
cell
cycl
arrest
also
inhibit
invas
metastasi
solid
tumor
fig
mechanist
modul
either
srcfak
focal
adhes
kinas
signal
cascad
lycorin
block
matrix
degrad
metalloproteinas
mmp
mediat
degrad
extracellular
matrix
lycorin
inhibit
breast
cancer
cell
invas
migrat
block
srcfakinvolv
pathway
fak
signal
cell
invas
involv
proteolyt
degrad
extracellular
matrix
mmp
fak
coordin
srcca
complex
interact
crk
initi
signal
jun
ntermin
kinas
jnk
mediat
transcript
activ
mmp
treatment
lycorin
significantli
decreas
pfak
psrc
pcjun
pjnk
breast
cancer
cell
line
demonstr
effect
lycorin
block
matrix
degrad
srcfak
signal
pathway
inhibit
migrat
invas
furthermor
lycorin
inhibitori
effect
epiderm
growth
factorinduc
epithelialmesenchym
transit
emt
number
studi
reveal
bind
promot
emtrel
transcript
factor
twist
modul
express
therebi
promot
emt
process
increas
cell
invas
migrat
prostat
cancer
cell
expos
lycorin
show
signific
epitheli
characterist
reduc
mesenchym
featur
decreas
express
ncadherin
vimentin
fibronectin
correspond
increas
express
ecadherin
revers
growth
factorinduc
emt
lycorin
associ
inhibit
express
twist
suppress
express
migrat
marker
twist
target
gene
lycorineinduc
downregul
twist
therebi
suppress
emt
directli
mediat
inhibit
also
suggest
potenti
target
lycorineinduc
anticanc
effect
signific
decreas
cell
viabil
observ
knockdown
prostat
cancer
cell
nonsmal
cell
lung
cancer
lycorin
effect
suppress
signal
emt
revers
apart
mention
effect
lycorin
also
modul
sever
signal
pathway
regul
growth
prolifer
cancer
cell
includ
jnk
pathway
phosphorakt
pathway
mekerk
pathway
jakstat
signal
pathway
structureact
relationship
sar
enabl
determin
chemic
structur
respons
target
biolog
activ
molecul
allow
chang
chemic
group
modifi
effect
potenc
bioavail
given
molecul
therefor
import
understand
structur
featur
bioactiv
compound
research
develop
compound
clinic
avail
drug
requir
structur
chemistri
lycorin
greatli
vari
depend
pharmacolog
activ
exampl
open
dioxolan
ring
result
loss
activ
dengu
hepat
c
viru
hcv
substitu
suitabl
group
posit
facilit
specif
bind
activ
wnt
signal
wnt
signal
pathway
import
develop
highli
conserv
lycorin
deriv
act
agonist
pathway
need
cec
singl
bond
thiazol
ringd
carbon
doubl
bond
ringc
vital
anti
plasmodi
activ
deriv
possess
free
hydroxyl
group
esterifi
acet
activ
although
disubstitut
free
hydroxyl
group
clearli
reduc
cytotox
unsatur
keton
either
posit
would
improv
hcv
inhibitori
activ
lycorin
keton
substitut
also
effect
antidengu
activ
lycorin
time
substitut
linear
aliphat
would
enhanc
activ
increas
carbon
chain
bulki
substitu
aromat
substitut
result
loss
activ
dengu
viru
hemecontain
monooxygenas
enzym
cytochrom
involv
detoxif
wide
varieti
xenobiot
includ
environment
toxin
drug
preliminari
structureact
relationship
point
either
substitut
bulki
substanc
lycorin
result
potent
inhibitori
activ
disubstitut
posit
moder
retriev
activ
unprotect
group
posit
also
necessari
antiparasit
activ
lycorin
deriv
lycorin
seri
amaryllidacea
alkaloid
requir
hydrogenbond
acceptor
acetylcholinesteras
butyrylcholinesteras
inhibitori
activ
lipophil
substitu
increas
activ
howev
oxid
suppos
deactiv
compound
inhibitori
effect
common
structur
inact
characterist
need
pharmacolog
activ
lycorin
deriv
includ
planar
molecul
basic
nitrogen
free
hydroxyl
group
numer
studi
aim
determin
sar
lycorin
found
sever
structur
featur
requir
antitumor
activ
tabl
fig
presenc
unalt
hydroxyl
group
posit
origin
form
essenti
antitumor
properti
lycorin
howev
analog
incorpor
chang
diol
cring
steric
bulki
substitu
well
toler
activ
like
attribut
intracellular
nucleophil
substitut
deriv
lycorin
water
although
hydrophob
element
cring
part
pharmacophor
assist
molecul
cell
penetr
substitut
posit
lack
abil
intracellular
hydrolysi
either
inact
moder
activ
presenc
nucleophil
site
cring
posit
also
structur
featur
requir
inhibit
amino
acid
biosynthesi
lycorin
absolut
requir
presenc
basic
nitrogen
posit
bring
quatern
incorpor
methyl
iodid
amid
nitrogen
provid
nonbas
charact
nitrogen
atom
result
loss
activ
except
rule
ringc
aromat
lycorin
analog
howev
activ
cancer
cell
line
anoth
structur
featur
requir
antitumor
activ
lycorin
stereochemistri
conform
freedom
cring
intact
b
cring
dring
requir
antitumor
effect
inhibit
ascorb
acid
synthesi
function
lycorin
dihydro
deriv
cring
show
absenc
antitumor
activ
howev
transposit
doubl
bond
cring
prove
equipot
lycorin
addit
deriv
open
conform
are
retain
similar
activ
lycorin
suggest
ring
constitut
structur
featur
essenti
antitumor
activ
featur
might
provid
use
guidelin
futur
analog
design
lipophil
conjug
longchain
fatti
acid
although
deriv
fatti
acid
conjug
show
elev
potenc
prove
chemic
stabl
ph
rang
furthermor
difficulti
penetr
cell
lycorin
deriv
highli
hydrophil
substitu
render
inact
despit
extens
research
pharmacolog
activ
lycorin
littl
known
pharmacokinet
due
lack
reliabl
method
pharmacokinet
studi
lycorin
preclin
studi
shown
signific
differ
pharmacokinet
paramet
lycorin
either
intraven
iv
intraperiton
ip
administr
howev
paramet
vari
method
appli
pharmacokinet
studi
maximum
plasma
concentr
c
max
area
curv
auc
lycorin
increas
dose
although
proport
gener
plasma
halflif
lycorin
dose
mgkg
h
maximum
concentr
max
reach
around
min
lycorin
galanthamin
abund
alkaloid
isol
amaryllidacea
plant
us
food
drug
administr
fda
alreadi
approv
galanthamin
prescript
drug
although
compound
possess
similar
chemic
structur
pharmacokinet
paramet
follow
oral
administr
found
differ
auc
lycorin
higher
galanthamin
howev
galanthamin
found
absorb
quickli
elimin
slowli
bodi
lycorin
probabl
due
metabol
statu
differ
intestin
andor
liver
lycorin
extens
distribut
tissu
anim
bodi
liver
spleen
heart
brain
lung
kidney
stomach
undetect
within
h
administr
regardless
rout
min
postadministr
concentr
lycorin
higher
kidney
lower
liver
impli
larg
quantiti
lycorin
elimin
kidney
may
metabol
liver
vivo
experi
beagl
dog
analyz
plasma
bp
vitro
incub
rat
liver
microsom
rlm
also
found
phasei
metabolit
confirm
metabol
site
lycorin
liver
furthermor
electrochem
ec
metabol
simul
suggest
lycorin
undergo
loss
water
form
phasei
metabolit
ungeremin
howev
phaseii
conjug
product
found
bp
rlm
ec
studi
phenotyp
screen
natur
compound
follow
identif
new
potenti
therapeut
target
indispens
tumor
develop
specif
target
lycorineinduc
anticanc
effect
identifi
far
howev
studi
provid
sever
potenti
target
lycorin
action
includ
famili
protein
hdac
stat
given
lycorin
induc
multipl
antineoplast
effect
exist
divers
molecular
target
lycorin
probabl
nonetheless
specif
molecular
target
lycorin
enzym
receptor
dna
rna
materi
investig
studi
direct
pharmacokinet
safeti
toxicolog
featur
achiev
better
understand
bioavail
metabol
tissu
distribut
behavior
compound
high
capabl
lycorin
combat
cancer
offer
motiv
medicin
organ
chemist
investig
chemistri
activ
moieti
associ
alkaloid
make
compound
bioavail
lower
toxic
worth
mention
point
formul
mannosyl
lycorineol
acid
nanoemuls
show
improv
lipophil
cellular
uptak
lycorin
prefer
growth
inhibit
activ
consid
activ
lycorin
resist
cell
potenti
combin
drug
explor
mechan
lycorin
context
resist
singl
agent
combin
drug
need
furthermor
better
understand
mechan
metabol
lycorin
basic
molecular
biolog
biochem
investig
continu
concern
high
morbid
cancer
worldwid
fewer
effect
therapi
right
time
work
natur
compound
improv
present
cancer
treatment
clinic
set
amaryllidacea
alkaloid
lycorin
prove
potent
anticanc
molecul
work
low
concentr
evid
well
toler
anim
articl
outlin
anticanc
mechan
lycorin
discuss
structur
characterist
relat
activ
molecul
pharmacolog
aspect
associ
studi
summar
review
provid
biologist
chemist
ration
explor
lycorin
bring
natur
compound
bench
bedsid
mridul
roy
design
review
review
literatur
draft
manuscript
long
liang
xiaojuan
xiao
peifu
feng
review
literatur
mao
ye
jing
liu
develop
idea
design
review
analyz
interpret
data
revis
manuscript
author
declar
conflict
interest
